Breadcrumb

Faculty News

Chengkai Dai appointed to Senior Investigator at CCR

The CCR community congratulates Chengkai Dai, Ph.D., who has been appointed Senior Investigator in the Mouse Cancer Genetics Program. Dai’s laboratory is a pioneer in the field of proteomic instability of cancer. His ongoing research focuses on the molecular mechanisms through which proteomic instability may affect genomic stability, cell invasion and autophagy, areas which hold promise to unveil new molecular pathways that could be targeted in cancer therapy.

Read More

Three CCR researchers elected to the National Academy of Sciences

Steven A. Rosenberg, M.D, Ph.D., Chief of the Surgery BranchGiorgio Trinchieri, M.D., Chief of the Laboratory of Integrative Cancer Immunology, and Sandra L. Wolin, M.D., Ph.D., Chief of the RNA Biology Laboratory, were elected as 2024 members of the National Academy of Sciences in recognition of their distinguished and continuing achievements in original research. The Academy is committed to furthering science in America, and its members are outstanding contributors to the international scientific community.

Read More

Jung-Min Lee elected to the American Society for Clinical Investigation

Jung-Min Lee, M.D., Senior Investigator in the Women’s Malignancies Branch, was elected to the American Society for Clinical Investigation. The organization seeks to support scientific efforts, educational needs and clinical aspirations of physician-scientists to improve the health of all people. Lee was selected for her merit as an internationally recognized expert in ovarian cancer and for being a highly respected clinician and physician-scientist. 

Read More

Jung-Min Lee appointed Senior Investigator at CCR

The CCR community congratulates Jung-Min Lee, M.D., who has been appointed as a Senior Investigator in the Women’s Malignancies Branch. Lee’s research focuses on developing targeted therapies for ovarian carcinoma. Her studies have identified key proteins of DNA damage response pathways as therapeutic targets, opening up possibilities for novel therapies for this disease. Her research also emphasizes the collection of patient samples to better understand treatment response and tumor biology.

Read More

Leah Cook appointed Senior Investigator at CCR

The CCR community welcomes Leah M. Cook, Ph.D., who has been appointed as a Senior Investigator in the Cancer Innovation Laboratory. She is a cancer biologist with a focus on metastasis and the metastasis microenvironment. The goal of her research program is to identify mechanisms associated with bone metastatic prostate cancer and specifically, the underpinnings of the immune-tumor bone environment that contribute to metastatic disease.

Read More

First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma

On February 16, 2024, the Food and Drug Administration approved lifileucel (Amtagvi), the first cancer treatment that uses immune cells called tumor-infiltrating lymphocytes (TILs), for some people with advanced melanoma. TIL therapy was pioneered in the 1980s by Steven A. Rosenberg, M.D., Chief of the Surgery Branch, and the final approval of this treatment has taken years of clinical trial research and ongoing partnerships among multiple institutions.

Read More